Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies

Amanda J Lee, Triglyceride Coronary Disease Genetics Consortium and Emerging risk factors collaboration

Research output: Contribution to journalArticle

440 Citations (Scopus)

Abstract

Background Whether triglyceride-mediated pathways are causally relevant to coronary heart disease is uncertain. We studied a genetic variant that regulates triglyceride concentration to help judge likelihood of causality.Methods We assessed the -1131T>C (rs662799) promoter polymorphism of the apolipoprotein A5 (APOA5) gene in relation to triglyceride concentration, several other risk factors, and risk of coronary heart disease. We compared disease risk for genetically-raised triglyceride concentration (20 842 patients with coronary heart disease, 35 206 controls) with that recorded for equivalent differences in circulating triglyceride concentration in prospective studies (302 430 participants with no history of cardiovascular disease; 12 785 incident cases of coronary heart disease during 2.79 million person-years at risk). We analysed -1131T>C in 1795 people without a history of cardiovascular disease who had information about lipoprotein concentration and diameter obtained by nuclear magnetic resonance spectroscopy.Findings The minor allele frequency of -1131T>C was 8% (95% CI 7-9). -1131T>C was not significantly associated with several non-lipid risk factors or LDL cholesterol, and it was modestly associated with lower HDL cholesterol (mean difference per C allele 3.5% [95% CI 2.6-4.6]; 0.053 mmol/L [0.039-0.068]), lower apolipoprotein AI (1.3% [0.3-2.3]; 0.023 g/L [0.005-0.041]), and higher apolipoprotein B (3.2% [1.3-5.1]; 0.027 g/L [0.011-0.043]). By contrast, for every C allele inherited, mean triglyceride concentration was 16.0% (95% CI 12.9-18.7), or 0.25 mmol/L (0.20-0.29), higher (p=4.4x10(-24)). The odds ratio for coronary heart disease was 1.18 (95% CI 1.11-1.26; p=2.6x10(-7)) per C allele, which was concordant with the hazard ratio of 1.10 (95% CI 1.08-1.12) per 16% higher triglyceride concentration recorded in prospective studies. -1131T>C was significantly associated with higher VLDL particle concentration (mean difference per C allele 12.2 nmol/L [95% CI 7.7-16.7]; p=9.3x10(-8)) and smaller HDL particle size (0.14 nm [0.08-0.20]; p=7.0x10(-5)), factors that could mediate the effects of triglyceride.Interpretation These data are consistent with a causal association between triglyceride-mediated pathways and coronary heart disease.

Original languageEnglish
Pages (from-to)1634-1639
Number of pages6
JournalThe Lancet
Volume375
Issue number9726
DOIs
Publication statusPublished - 8 May 2010

Fingerprint

Coronary Disease
Triglycerides
Alleles
Cardiovascular Diseases
Prospective Studies
Apolipoproteins
Apolipoprotein A-I
Apolipoproteins B
Particle Size
Gene Frequency
Causality
LDL Cholesterol
HDL Cholesterol
Lipoproteins
Magnetic Resonance Spectroscopy
Odds Ratio
Genes

Cite this

Lee, A. J., & Triglyceride Coronary Disease Genetics Consortium and Emerging risk factors collaboration (2010). Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. The Lancet, 375(9726), 1634-1639. https://doi.org/10.1016/S0140-6736(10)60545-4

Triglyceride-mediated pathways and coronary disease : collaborative analysis of 101 studies. / Lee, Amanda J; Triglyceride Coronary Disease Genetics Consortium and Emerging risk factors collaboration.

In: The Lancet, Vol. 375, No. 9726, 08.05.2010, p. 1634-1639.

Research output: Contribution to journalArticle

Lee, AJ & Triglyceride Coronary Disease Genetics Consortium and Emerging risk factors collaboration 2010, 'Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies', The Lancet, vol. 375, no. 9726, pp. 1634-1639. https://doi.org/10.1016/S0140-6736(10)60545-4
Lee AJ, Triglyceride Coronary Disease Genetics Consortium and Emerging risk factors collaboration. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. The Lancet. 2010 May 8;375(9726):1634-1639. https://doi.org/10.1016/S0140-6736(10)60545-4
Lee, Amanda J ; Triglyceride Coronary Disease Genetics Consortium and Emerging risk factors collaboration. / Triglyceride-mediated pathways and coronary disease : collaborative analysis of 101 studies. In: The Lancet. 2010 ; Vol. 375, No. 9726. pp. 1634-1639.
@article{57e77e26bda24a7a919194b4ec43e723,
title = "Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies",
abstract = "Background Whether triglyceride-mediated pathways are causally relevant to coronary heart disease is uncertain. We studied a genetic variant that regulates triglyceride concentration to help judge likelihood of causality.Methods We assessed the -1131T>C (rs662799) promoter polymorphism of the apolipoprotein A5 (APOA5) gene in relation to triglyceride concentration, several other risk factors, and risk of coronary heart disease. We compared disease risk for genetically-raised triglyceride concentration (20 842 patients with coronary heart disease, 35 206 controls) with that recorded for equivalent differences in circulating triglyceride concentration in prospective studies (302 430 participants with no history of cardiovascular disease; 12 785 incident cases of coronary heart disease during 2.79 million person-years at risk). We analysed -1131T>C in 1795 people without a history of cardiovascular disease who had information about lipoprotein concentration and diameter obtained by nuclear magnetic resonance spectroscopy.Findings The minor allele frequency of -1131T>C was 8{\%} (95{\%} CI 7-9). -1131T>C was not significantly associated with several non-lipid risk factors or LDL cholesterol, and it was modestly associated with lower HDL cholesterol (mean difference per C allele 3.5{\%} [95{\%} CI 2.6-4.6]; 0.053 mmol/L [0.039-0.068]), lower apolipoprotein AI (1.3{\%} [0.3-2.3]; 0.023 g/L [0.005-0.041]), and higher apolipoprotein B (3.2{\%} [1.3-5.1]; 0.027 g/L [0.011-0.043]). By contrast, for every C allele inherited, mean triglyceride concentration was 16.0{\%} (95{\%} CI 12.9-18.7), or 0.25 mmol/L (0.20-0.29), higher (p=4.4x10(-24)). The odds ratio for coronary heart disease was 1.18 (95{\%} CI 1.11-1.26; p=2.6x10(-7)) per C allele, which was concordant with the hazard ratio of 1.10 (95{\%} CI 1.08-1.12) per 16{\%} higher triglyceride concentration recorded in prospective studies. -1131T>C was significantly associated with higher VLDL particle concentration (mean difference per C allele 12.2 nmol/L [95{\%} CI 7.7-16.7]; p=9.3x10(-8)) and smaller HDL particle size (0.14 nm [0.08-0.20]; p=7.0x10(-5)), factors that could mediate the effects of triglyceride.Interpretation These data are consistent with a causal association between triglyceride-mediated pathways and coronary heart disease.",
author = "Lee, {Amanda J} and {Triglyceride Coronary Disease Genetics Consortium and Emerging risk factors collaboration}",
year = "2010",
month = "5",
day = "8",
doi = "10.1016/S0140-6736(10)60545-4",
language = "English",
volume = "375",
pages = "1634--1639",
journal = "The Lancet",
issn = "0140-6736",
publisher = "ACADEMIC PRESS INC ELSEVIER SCIENCE",
number = "9726",

}

TY - JOUR

T1 - Triglyceride-mediated pathways and coronary disease

T2 - collaborative analysis of 101 studies

AU - Lee, Amanda J

AU - Triglyceride Coronary Disease Genetics Consortium and Emerging risk factors collaboration

PY - 2010/5/8

Y1 - 2010/5/8

N2 - Background Whether triglyceride-mediated pathways are causally relevant to coronary heart disease is uncertain. We studied a genetic variant that regulates triglyceride concentration to help judge likelihood of causality.Methods We assessed the -1131T>C (rs662799) promoter polymorphism of the apolipoprotein A5 (APOA5) gene in relation to triglyceride concentration, several other risk factors, and risk of coronary heart disease. We compared disease risk for genetically-raised triglyceride concentration (20 842 patients with coronary heart disease, 35 206 controls) with that recorded for equivalent differences in circulating triglyceride concentration in prospective studies (302 430 participants with no history of cardiovascular disease; 12 785 incident cases of coronary heart disease during 2.79 million person-years at risk). We analysed -1131T>C in 1795 people without a history of cardiovascular disease who had information about lipoprotein concentration and diameter obtained by nuclear magnetic resonance spectroscopy.Findings The minor allele frequency of -1131T>C was 8% (95% CI 7-9). -1131T>C was not significantly associated with several non-lipid risk factors or LDL cholesterol, and it was modestly associated with lower HDL cholesterol (mean difference per C allele 3.5% [95% CI 2.6-4.6]; 0.053 mmol/L [0.039-0.068]), lower apolipoprotein AI (1.3% [0.3-2.3]; 0.023 g/L [0.005-0.041]), and higher apolipoprotein B (3.2% [1.3-5.1]; 0.027 g/L [0.011-0.043]). By contrast, for every C allele inherited, mean triglyceride concentration was 16.0% (95% CI 12.9-18.7), or 0.25 mmol/L (0.20-0.29), higher (p=4.4x10(-24)). The odds ratio for coronary heart disease was 1.18 (95% CI 1.11-1.26; p=2.6x10(-7)) per C allele, which was concordant with the hazard ratio of 1.10 (95% CI 1.08-1.12) per 16% higher triglyceride concentration recorded in prospective studies. -1131T>C was significantly associated with higher VLDL particle concentration (mean difference per C allele 12.2 nmol/L [95% CI 7.7-16.7]; p=9.3x10(-8)) and smaller HDL particle size (0.14 nm [0.08-0.20]; p=7.0x10(-5)), factors that could mediate the effects of triglyceride.Interpretation These data are consistent with a causal association between triglyceride-mediated pathways and coronary heart disease.

AB - Background Whether triglyceride-mediated pathways are causally relevant to coronary heart disease is uncertain. We studied a genetic variant that regulates triglyceride concentration to help judge likelihood of causality.Methods We assessed the -1131T>C (rs662799) promoter polymorphism of the apolipoprotein A5 (APOA5) gene in relation to triglyceride concentration, several other risk factors, and risk of coronary heart disease. We compared disease risk for genetically-raised triglyceride concentration (20 842 patients with coronary heart disease, 35 206 controls) with that recorded for equivalent differences in circulating triglyceride concentration in prospective studies (302 430 participants with no history of cardiovascular disease; 12 785 incident cases of coronary heart disease during 2.79 million person-years at risk). We analysed -1131T>C in 1795 people without a history of cardiovascular disease who had information about lipoprotein concentration and diameter obtained by nuclear magnetic resonance spectroscopy.Findings The minor allele frequency of -1131T>C was 8% (95% CI 7-9). -1131T>C was not significantly associated with several non-lipid risk factors or LDL cholesterol, and it was modestly associated with lower HDL cholesterol (mean difference per C allele 3.5% [95% CI 2.6-4.6]; 0.053 mmol/L [0.039-0.068]), lower apolipoprotein AI (1.3% [0.3-2.3]; 0.023 g/L [0.005-0.041]), and higher apolipoprotein B (3.2% [1.3-5.1]; 0.027 g/L [0.011-0.043]). By contrast, for every C allele inherited, mean triglyceride concentration was 16.0% (95% CI 12.9-18.7), or 0.25 mmol/L (0.20-0.29), higher (p=4.4x10(-24)). The odds ratio for coronary heart disease was 1.18 (95% CI 1.11-1.26; p=2.6x10(-7)) per C allele, which was concordant with the hazard ratio of 1.10 (95% CI 1.08-1.12) per 16% higher triglyceride concentration recorded in prospective studies. -1131T>C was significantly associated with higher VLDL particle concentration (mean difference per C allele 12.2 nmol/L [95% CI 7.7-16.7]; p=9.3x10(-8)) and smaller HDL particle size (0.14 nm [0.08-0.20]; p=7.0x10(-5)), factors that could mediate the effects of triglyceride.Interpretation These data are consistent with a causal association between triglyceride-mediated pathways and coronary heart disease.

U2 - 10.1016/S0140-6736(10)60545-4

DO - 10.1016/S0140-6736(10)60545-4

M3 - Article

VL - 375

SP - 1634

EP - 1639

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 9726

ER -